The Innovative Medicines Initiative‘s EPAD (European Prevention of Alzheimer’s Dementia Consortium) announced the internal release of the baseline data from the first 1500 research participants (V1500.0). The dataset is part of its Longitudinal Cohort Study (Solomon et al., 2017). The data set is available to all EPAD partners and Trial Delivery Centres for an embargoed period of 6 months. This also means that access will be opened to the entire research community in May 2020.
EPAD is part of a global initiative that will make a fundamental difference to the understanding and management of Alzheimer’s disease in people with very early or no symptoms at all. This could be a game-changer. It is only possible because of the absolute commitment of academics, industry, policy makers and the public to work hand in hand to defeat this global threat.
Prof Craig Ritchie
EPAD Co-coordinator and Professor of the Psychiatry of Ageing at the University of Edinburgh
The V1500.0 – 1,500 is the number of sequentially recruited research participants and ‘.0’ refers to the data collected at the baseline visit – data release represents the second formal data release from the EPAD project. The data sets are made available via secure online workspaces in order to facilitate collaboration between people and teams with similar research aims.
Access to V500.0 data already public
The previous V500.0 data release recently went into open and external access in November 2019. Academic researchers and institutions from all over the world are invited to access the EPAD Research Access Process and begin the application process by visiting the EPAD LCS Research Access webpage, where you will find a variety of resources to support your research.You can read about how to access the first wave of data here: https://www.imi-neuronet.org/european-prevention-alzheimers-dementia-releases-data/
If you experience any technical issues or if you want more information please submit your query to firstname.lastname@example.org.